摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(decyloxy)benzaldehyde | 24083-15-6

中文名称
——
中文别名
——
英文名称
3-(decyloxy)benzaldehyde
英文别名
3-Decoxybenzaldehyde
3-(decyloxy)benzaldehyde化学式
CAS
24083-15-6
化学式
C17H26O2
mdl
MFCD12030660
分子量
262.392
InChiKey
AZYPIVMYLWEZDD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    374.3±15.0 °C(Predicted)
  • 密度:
    0.958±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.9
  • 重原子数:
    19
  • 可旋转键数:
    11
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.588
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(decyloxy)benzaldehyde盐酸 、 sodium hydride 作用下, 以 四氢呋喃甲醇 为溶剂, 生成 (E)-(S)-4-Amino-1-(3-decyloxy-phenyl)-5-hydroxy-pent-1-en-3-one; hydrochloride
    参考文献:
    名称:
    Syntheses of sphingosine-1-phosphate analogues and their interaction with EDG/S1P receptors
    摘要:
    Sphingosine-I-phosphate (SIP) is an important regulator of a wide variety of biological processes acting as an endogenous ligand to EDG/S1P receptors. In an effort to establish structure-activity relationship between EDG/S1P and ligands, we report herein homology modeling study of EDG-1/S1P(1), syntheses of S I P analogues, and cell based binding affinity study for EDG/S1P receptors. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.03.001
  • 作为产物:
    描述:
    癸醇间羟基苯甲醛三苯基膦偶氮二甲酸二乙酯 作用下, 以 四氢呋喃 为溶剂, 以73%的产率得到3-(decyloxy)benzaldehyde
    参考文献:
    名称:
    Syntheses and antifungal activity of pseudomycin side-chain analogues. Part 1
    摘要:
    We have described herein the syntheses of three novel series of aromatic ring containing pseudomycin side-chain analogues. Preliminary biological evaluations of these analogues clearly indicate that it is possible to synthesize rigid pseudomycin sidechain analogues without compromising in vitro antifungal activity. (C) 2000 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(00)00423-6
点击查看最新优质反应信息

文献信息

  • (Methoxyalkyl)thiazoles: a new series of potent, selective, and orally active 5-lipoxygenase inhibitors displaying high enantioselectivity
    作者:T. Geoffrey C. Bird、Pierre Bruneau、Graham C. Crawley、Martin P. Edwards、Stephen J. Foster、Jean Marc Girodeau、John F. Kingston、Rodger M. McMillan
    DOI:10.1021/jm00111a038
    日期:1991.7
    this series which is exemplified by 1-[3-(naphth-2-ylmethoxy)phenyl]-1-(thiazol-2-yl)propy l methyl ether (2d, ICI211965). 2d inhibits cell-free guinea pig 5-LPO activity, LTC4 synthesis in plasma free mouse macrophages, and LTB4 synthesis in rat and human blood (IC50s 0.1 microM, 8 nM, 0.5 microM, and 0.4 microM, respectively) but does not inhibit the synthesis of cyclooxygenase products at concentrations
    (甲氧基烷基)噻唑是新颖的5-脂氧合酶(5-LPO)抑制剂,既不是氧化还原剂也不是铁螯合剂。考虑到酶活性位点的假设模型导致了该系列,该系列以1- [3-(萘-2-基甲氧基)苯基] -1-(噻唑-2-基)丙基甲基醚(2d,ICI211965)为例)。2d抑制无细胞豚鼠5-LPO活性,无血浆小鼠巨噬细胞中的LTC4合成以及大鼠和人类血液中的LTB4合成(IC50分别为0.1 microM,8 nM,0.5 microM和0.4 microM),但不抑制在巨噬细胞中合成浓度高达50 microM,在血液中合成浓度高达100 microM的环氧合酶产物。2d在大鼠中具有口服活性(给药后1小时内在血液中离体ED50 10 mg / kg)。SAR研究表明,高体外效力需要甲氧基,噻唑基,和萘基,并且主要取决于取代方式。(甲氧基烷基)噻唑是手性的。1-甲氧基-6-(萘-2-基甲氧基)-1-(噻唑-2-基
  • Synthesis and Structure-Activity Relationships of Novel Benzylamine-Type Antifungals as Butenafine-Related Antimycotics
    作者:Jürgen Krauss、Martina Stadler、Franz Bracher
    DOI:10.1002/ardp.201600342
    日期:2017.5
    Benzylamine‐type antimycotics like naftifine, butenafine, or terbinafine are a well‐known class of antimycotics since the 1980s. The following paper describes the synthesis and biological evaluation of a series of novel benzylamine‐type antimycotics characterized by an isooctyl side chain and various substituents at the benzylamine moiety. The compounds were prepared from benzaldehyde derivatives and
    自 1980 年代以来,苄胺类抗真菌药如萘替芬、布替萘芬或特比萘芬是一类众所周知的抗真菌药。以下论文描述了一系列以异辛基侧链和苄胺部分的各种取代基为特征的新型苄胺型抗真菌剂的合成和生物学评价。这些化合物是由苯甲醛衍生物和 2-氨基-6-甲基庚烷通过用三乙酰氧基硼氢化钠还原胺化,然后用氯化氢沉淀制备的。所得化合物的抗真菌活性在琼脂扩散试验中针对酵母 C. glabrata 和 Yarrowia lipolytica、霉菌黑曲霉和皮肤癣菌 H. burtonii 进行评估。还在针对酵母光滑念珠菌和皮肤癣菌 H.burtonii 的微量稀释试验中测试了这些化合物,以确定最小抑制浓度 (MIC)。具有芳香醚侧链或短烷基醚侧链的化合物对光滑念珠菌显示出显着的抗真菌活性,与特比萘芬或克霉唑相当。
  • AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY
    申请人:WELLSTAT THERAPEUTICS CORPORATION
    公开号:US20150361077A1
    公开(公告)日:2015-12-17
    Amine compounds having activity against inflammation, fungi, unicellular parasitic microorganisms, and cancer are described. The compounds contain a monocyclic, bicyclic, or tricyclic aromatic ring having one, two, or three ring nitrogen atoms.
    本文描述了对炎症、真菌、单细胞寄生微生物和癌症具有活性的胺化合物。这些化合物包含一个单环、双环或三环芳香环,其中含有一个、两个或三个环氮原子。
  • Synergistic Enhancement of Luminescent and Ferroelectric Properties through Multi‐Clipping of Tetraphenylethenes
    作者:Donghwan Kim、Hoang Tran Thi Thuy、Byeonggwan Kim、Yanghyun Auh、Maxime Rémond、Kwang Keat Leong、Ting Liang、Jinbo Kim、Eunkyoung Kim
    DOI:10.1002/adfm.202208157
    日期:2023.1
    Synergistically enhancing luminescent and ferroelectric (SELF) properties are observed from a tetraphenylethene (TP) substituted with clipping groups (C), where the C is consisting of a 4-[3,5-bis-(3-decyloxy-styryl)-styryl]-phenyl (DOS) unit. The DOS units of TPCn are self-assembled via intermolecular interaction to clip themselves and induce TP aggregation, as evidenced by clip-induced quenching
    从被剪切基团 ( C ) 取代的四苯乙烯 ( TP )中观察到协同增强的发光和铁电 ( SELF ) 特性,其中 C 由 4-[3,5-双-(3-癸氧基-苯乙烯基)-苯乙烯基组成]-苯基(DOS)单元。TPCn 的 DOS 单元通过分子间相互作用自组装以夹住自身并诱导 TP 聚集,DOS 单元 ( E clip ) 的夹子诱导发射猝灭伴随着 TP 的聚集诱导发射增强 ( E AIE ) 证明了这一点。TPC4 在稀氯仿溶液和大E AIE中表现出强烈的光致发光在水性 (>50%) THF 溶液中。TPCn 在薄膜状态下表现出 SELF 特性,具有高量子产率的光致发光 (>80%) 和铁电开关。由于引入了四个夹子,TPC4在室温下具有比 TPC1更高的剩余极化 ( P r = 2.27 µC cm -2 )。TPC4 成功用于发光电化学电池,在脉冲电流条件下达到超过 1290 cd m -2 。柔性基板上的
  • Alicyclic phospholipase A2 inhibitors
    申请人:Bristol-Myers Company
    公开号:EP0629604A2
    公开(公告)日:1994-12-21
    Compounds of Formula I: wherein the bonds between C₂ and C3 and/or between C₄ and C₅ are unsaturated; X = COOH, H, F, Cl, Br, I, COOR'', CONH₂, COR''', CHO, CH₂OH, CH₂OR''', OH, OR''', CF₃, C1-6 alkyl, C1-6 alkenyl, C1-6 haloalkyl, NO₂, P(O)(OH)₂, SO₂H, or SO₃H; R = substituted or unsubstituted alkyl, aryl, arylalkyl, alkenyl, or arylalkenyl groups, with the proviso that each of these groups must have 6 or more carbons (preferably 6 to 30) and R cannot be R' = H or C1-6 alkyl; R'' = H, C1-6 alkyl, C(R³)₂OC(O)R⁴, CH₂CH₂NR⁵R⁶, CH₂CH₂CH₂NR⁵R⁶, CH₂C(O)N(R⁶)₂, or other groups yielding physiologically hydrolyzable esters; R''' = C1-6 alkyl; R³ = H, CH₃, C₂H₅, CH₃CH₂CH₂ (with R³'s being the same or different); R⁴ = C6-12 aryl, C1-7 linear, branched or cyclic alkyl, or C1-7 linear, branched or cyclic alkoxy; R⁵ = R⁶, or when linked with R⁶, is a C₃-C₆ cycloalkyl or a -CH₂CH₂OCH₂CH₂-group; and R⁶ = C1-3 alkyl; and pharmaceutically-acceptable salts thereof are effective phospholipase A₂ (PLA₂) inhibitors.
    式 I 的化合物: 其中 C₂ 与 C3 之间和/或 C₄ 与 C₅ 之间的键为不饱和键; X = COOH、H、F、Cl、Br、I、COOR''、CONH₂、COR'''、CHO、CH₂OH、CH₂OR'''、OH、OR'''、CF₃、C1-6 烷基、C1-6 烯基、C1-6 卤代烷基、NO₂、P(O)(OH)₂、SO₂H 或 SO₃H; R = 取代或未取代的烷基、芳基、芳烷基、烯基或芳烷烯基,但这些基团都必须具有 6 个或更多的碳原子(最好是 6 至 30 个),且 R 不能是 R' = H 或 C1-6 烷基; R''=H、C1-6 烷基、C(R³)₂OC(O)R⁴、CH₂CH₂NR⁵R⁶、CH₂CH₂CH₂NR⁵R⁶、CH₂C(O)N(R⁶)₂ 或其他可产生生理性水解酯的基团; R''' = C1-6 烷基; R³ = H、CH₃、C₂H₅、CH₃CH₂CH₂(R³'s 相同或不同); R⁴ = C6-12 芳基,C1-7 直链、支链或环状烷基,或 C1-7 直链、支链或环状烷氧基; R⁵ = R⁶,或当与 R⁶ 连接时,为 C₃-C₆ 环烷基或-CH₂CH₂OCH₂CH₂基团;以及 R⁶ = C1-3 烷基; 及其药学上可接受的盐是有效的磷脂酶 A₂(PLA₂)抑制剂。
查看更多